{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:48:12Z","timestamp":1790480892258,"version":"4.1.0"},"reference-count":38,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA77598"],"award-info":[{"award-number":["P30 CA77598"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The proto-oncogene MET, the hepatocyte growth factor (HGF) receptor, is a transmembrane receptor tyrosine kinase (RTK) with a prominent role in tumor metastasis and resistance to anti-cancer therapies. Melanoma demonstrates relatively frequent MET aberrations, including MET gene amplification. Concurrently, programmed death-ligand 1 (PD-L1), with its ability to evade anti-tumor immune responses, has emerged as a prominent therapeutic target in melanoma and other malignancies and its expression is used as a predictive biomarker of response to immunotherapy. We performed immunohistochemistry analysis of MET and PD-L1 in 18 human melanoma cell lines derived from both primary and metastatic lesions, and in a human melanoma tissue microarray containing one hundreds melanocytic lesions, including primary cutaneous melanomas, primary mucosal melanomas, metastatic melanomas and benign melanocytic nevi as controls. After color deconvolution, each core was segmented to isolate staining and calculate the percentage of positive cells. Overall, MET expression was higher in tumors with increased PD-L1 expression. Moreover, a robust correlation between MET and PD-L1 expression was found in samples from metastatic melanoma and not in primary cutaneous or mucosal melanoma. These data suggest that relative expression levels of these proteins in combination is a marker of advanced disease and testing for expression of these markers should be considered in patients with melanoma.<\/jats:p>","DOI":"10.3390\/cancers12071847","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T09:45:31Z","timestamp":1594374331000},"page":"1847","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Correlation of MET and PD-L1 Expression in Malignant Melanoma"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7313-514X","authenticated-orcid":false,"given":"Kyu Young","family":"Song","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA"},{"name":"Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Desar","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-918X","authenticated-orcid":false,"given":"Thomas","family":"Pengo","sequence":"additional","affiliation":[{"name":"University of Minnesota Informatics Institute, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Shanley","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center Biostatistics Core, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5352-0662","authenticated-orcid":false,"given":"Alessio","family":"Giubellino","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA"},{"name":"Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: Optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/cas.13156","article-title":"Hepatocyte growth factor\/MET in cancer progression and biomarker discovery","volume":"108","author":"Matsumoto","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: Rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Met, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-Genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/biomedicines3010138","article-title":"HGF\/Met-Signaling Contributes to Immune Regulation by Modulating Tolerogenic and Motogenic Properties of Dendritic Cells","volume":"3","author":"Hubel","year":"2015","journal-title":"Biomedicines"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nature14407","article-title":"MET is required for the recruitment of anti-tumoural neutrophils","volume":"522","author":"Finisguerra","year":"2015","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3389\/fimmu.2017.00961","article-title":"Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells","volume":"8","author":"Dong","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and Function of the PD-L1 Checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.canlet.2017.11.014","article-title":"Progress and challenges of predictive biomarkers of anti PD-1\/PD-L1 immunotherapy: A systematic review","volume":"414","author":"Teng","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00262-006-0272-1","article-title":"Contribution of the PD-L1\/PD-1 pathway to T-Cell exhaustion: An update on implications for chronic infections and tumor evasion","volume":"56","author":"Blank","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1074\/jbc.M114.612689","article-title":"Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression","volume":"290","author":"Balan","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41416-018-0315-3","article-title":"Met inhibition revokes IFNgamma-Induction of PD-1 ligands in MET-amplified tumours","volume":"120","author":"Martin","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?","volume":"39","author":"Fares","year":"2019","journal-title":"Am. Soc. Clin.Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meeting"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40257-017-0320-y","article-title":"Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond","volume":"19","author":"Zhou","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.ajpath.2019.08.002","article-title":"The Role of MET in Melanoma and Melanocytic Lesions","volume":"189","author":"Zhou","year":"2019","journal-title":"Am. J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00055","article-title":"Targeting the HGF\/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma","volume":"2018","author":"Oba","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"17795","DOI":"10.18632\/oncotarget.14855","article-title":"MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor","volume":"8","author":"Caenepeel","year":"2017","journal-title":"Oncotarget"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic Classification of Cutaneous Melanoma","volume":"161","author":"Akbani","year":"2015","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.autrev.2014.11.013","article-title":"Hepatocyte growth factor: A regulator of inflammation and autoimmunity","volume":"14","author":"Molnarfi","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.15252\/embr.201744075","article-title":"Identification of a novel population of highly cytotoxic c-Met-Expressing CD8(+) T lymphocytes","volume":"18","author":"Benkhoucha","year":"2017","journal-title":"EMBO Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3389\/fimmu.2018.00517","article-title":"The Impact of the Epithelial-Mesenchymal Transition Regulator Hepatocyte Growth Factor Receptor\/Met on Skin Immunity by Modulating Langerhans Cell Migration","volume":"9","author":"Sagi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/his.13516","article-title":"Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis","volume":"73","author":"Loughrey","year":"2018","journal-title":"Histopathology"},{"key":"ref_29","unstructured":"Jenkins, R.W., and Fisher, D.E. Treatment of Advanced Melanoma in 2020 and Beyond. J. Investig. Dermatol., Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/32268150\/."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/cncr.30435","article-title":"Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma","volume":"123","author":"Lim","year":"2017","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-Genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1158\/2159-8290.CD-11-0175","article-title":"Durable complete response of metastatic gastric cancer with Anti-Met therapy followed by resistance at recurrence","volume":"1","author":"Catenacci","year":"2011","journal-title":"Cancer Discov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1158\/1078-0432.CCR-13-1836","article-title":"Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib\u00b1onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit","volume":"20","author":"Koeppen","year":"2014","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.29496","article-title":"Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma","volume":"67","author":"Bouattour","year":"2018","journal-title":"Hepatol. Baltim. Md"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.2017.72.2967","article-title":"Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer","volume":"35","author":"Choueiri","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am.Soc. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/7\/1847\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:49:18Z","timestamp":1760176158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/7\/1847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["cancers12071847"],"URL":"https:\/\/doi.org\/10.3390\/cancers12071847","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-22935\/v1","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,9]]}}}